【摘 要】
：
Eclipta prostrata (EP) is often prescribed in combination with glucocorticoid to treat glomerular nephritis,nephrotic syndrome,and IgA nephropathy in clinical practice of Traditional Chinese Medicine.
【机 构】
：
Department of Pharmacy,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou,Guangdong,Chin
论文部分内容阅读
Eclipta prostrata (EP) is often prescribed in combination with glucocorticoid to treat glomerular nephritis,nephrotic syndrome,and IgA nephropathy in clinical practice of Traditional Chinese Medicine.Previous studies from our laboratory revealed that co-administration of EP significantly increased the plasma concentration of prednisolone,while decreased the level of co-treated prednisone in rats.However,the underlying mechanism remains unclear.11β-Hydroxysteroid dehydrogenase (11β-HSD) belongs to the family of oxidoreductases that catalyze the inter-conversion of prednisone to active prednisolone.Therefore,the current study aimed to investigate the effects of EP on the activity and expression of 11β-HSD in rat liver and kidney.The results showed that orally administration of EP significantly increased the activity of 11β-HSD I in the liver and 11β-HSD II in the kidney by employing the microsomal incubation system.Moreover,gene and protein expression of 11β-HSD I and 11β-HSD II were also increased in rat liver and kidney,respectively.These results suggest that the effects of EP on 11β-HSD may attribute to the mechanism that administration of EP improves the efficacy and reduce adverse drug reactions of glucocorticoid in patients undergoing combinational therapy.
其他文献
目的：建立IBS-D模型组和对照组结肠组织蛋白质双向电泳图谱,结合质谱技术鉴定并分析差异表达蛋白,对候选表达差异蛋白进行蛋白质功能和相关研究,进一步阐明IBS-D病理机制.方法：采用双向凝胶电泳法分离IBS-D模型组和正常对照组结肠粘膜差异蛋白,运用MALDI TOF/TOF串联飞行时间质谱仪进行鉴定,运用Gene Ontology和Pathway Studio生物信息学方法将所鉴定的差异蛋白进行
Background and purpose With the increase of age,increased susceptibility to apoptosis and senescence may contribute to proliferative and functional impairment of endothelial progenitor cells (EPCs).Th
目的：观察桑叶有效部位(总多糖、总黄酮、总生物碱)影响NF-κB通路对高胰岛素诱导人肝癌HepG2细胞胰岛素抵抗的改善作用.方法：以人肝癌HepG2细胞为研究对象,在含10μg﹒mL-1胰岛素的培养基中培养48h,建立IR-HepG2模型.实验分组：对照组,10μg﹒mL-1胰岛素处理组,总多糖组(MLP),总黄酮组(MLF),总生物碱(MLA)、小白菊内酯(PTL)处理组.采用葡萄糖氧化酶-过氧
目的：研究吉西他滨在不同时间点给药对于光制改变肝癌小鼠的治疗效果比较.方法：建立光制改变的肝癌小鼠模型,在8am,14pm,20pm,2am给予固定剂量的吉西他滨治疗,比较疗效的区别.结果：吉西他滨对于光制改变的肝癌小鼠具有治疗作用,光镜下可见吉西他滨治疗组小鼠的肺肝肾损伤较肝癌模型组减轻,肝肾功能改善(P＜0.05,8am、14pm、20pm组vs.肝癌模型组;P＜0.01,2am组vs.肝癌模
目的：研究金属有机骨架MIL-53作为药物载体装载抗肿瘤药5-FU,及其体外释药和MIL-53的细胞相容性.方法：以水热法制备金属有机骨架MIL-53,并通过透射电镜(TEM),X-射线粉末衍射(XRD),红外光谱(IR),热重分析(TG)对所得样品进行表征.以5-FU为模型药物,研究MIL-53载药、体外释药和载体MIL-53的细胞相容性.结果：XRD谱图与IR谱图确定了样品MIL-53的结构,
RNAi technology is taking strong position among the key therapeutic modalities,with dozens of siRNA-based programs entering and successfully progressing through clinical stages of drug development.To
目的：观察P2Y12、P2Y1和ITGB3基因多态性对PCI术后受阿司匹林和氯吡格雷抗血小板效应的影响.方法：520例冠心病患者经PCI术后接受阿司匹林和氯吡格雷联合抗血小板治疗.所有患者行PCI术前每天口服给予氯吡格雷负荷剂量300mg和阿司匹林负荷剂量100mg,术后改为每天口服氯吡格雷75mg,维持剂量,服用6个月以上,口服阿司匹林100mg,维持剂量,服用1年,如患者出现胃出血等不宜服用时
目的：考察中国异基因造血干细胞移植(Allogeneic Hematopoietic Stem Cells Transplantation,allo-HSCT)术后患者环孢素A(Cyclosporine A,CsA)群体药代动力学(population pharmacokinetics,PPK)特征,为临床设计个体化给药方案提供参考.方法：回顾性收集32名allo-HSCT术后使用CsA治疗患者常
目的：研究南蛇藤(Celastrus orbiculatus Thunb.)叶子降血糖有效部位的化学成分.方法：采用柱色谱和薄层色谱分离南蛇藤叶子降血糖有效部位中的化学成分;用IR、MS、NMR等波谱技术鉴定结构.结果：分离并鉴定了7个化合物,分别为山奈酚(1)、槲皮素(2)、山奈酚-7-O-α-L-鼠李糖苷(3)、山奈酚-3,7-二-O-α-L-鼠李糖苷(4)、槲皮素-3-O-β-D-葡萄糖苷(
目的：建立双乌宣痹颗粒的质量标准方法：采用TLC法对双乌宣痹颗粒中青蒿、制川乌、白芍等药材进行定性鉴别,采用HPLC法测定双乌宣痹颗粒中芍药苷的含量.结果：薄层色谱斑点清晰、分离效果好、且阴性无干扰.芍药苷在0.32～10.10μg范围呈现良好的线性关系(r=0.9998),平均回收率97.21％,RSD为2.56％.结论：该方法准确可靠、专属性强、重复性好,可以作为控制双乌宣痹颗粒质量的有效方法